# What a Healthcare Investment Due-Diligence Report Should Include: A Complete Checklist > A rigorous healthcare investment due-diligence report covers regulatory status, clinical evidence, intellectual property, financial health, and management integrity across verified primary sources. This guide tells you exactly what to demand in each section and where to find the underlying data. ## What Should a Healthcare Investment Due-Diligence Report Cover? A healthcare investment due-diligence report must answer seven core questions: Is the regulatory pathway clear? Does clinical evidence support the claims? Is the IP defensible? Are the financials sound? Is management credible? Are there undisclosed liabilities? And does the market opportunity hold up under scrutiny? Every section below maps directly to one of those questions, with the exact primary sources you should verify. ## Why Healthcare Due Diligence Is Different From General Equity Research Healthcare deals fail at rates that general-market investors rarely anticipate because the risk drivers are domain-specific. A promising revenue model collapses the moment an FDA Complete Response Letter arrives. A blockbuster pipeline asset evaporates when a Phase III trial misses its primary endpoint. Reimbursement codes disappear in a single CMS Final Rule. Standard financial analysis misses all of this. Healthcare due diligence therefore demands parallel tracks: scientific, regulatory, legal, and financial, all cross-referenced against each other. ## Section 1: Regulatory Status and Pathway Analysis Start here because regulatory risk is often binary. Check the FDA's public databases (drugs.fda.gov, 510(k) database, PMA database) for current approval status, any warning letters on FDA.gov, and any import alerts. For combination products, confirm the lead center assignment. For diagnostics, verify CLIA complexity classification. Key questions to answer: - What approval pathway is the company pursuing and is it realistic for the product profile? - Has the FDA issued any formal safety communications, recalls, or enforcement actions against this company or its manufacturing sites? - Is there a Breakthrough, Fast Track, or Priority Review designation, and what are the actual implications for timeline? Common mistake: Investors accept management's summary of regulatory status without pulling the actual FDA correspondence or checking the FDA inspection database (FOIA-available) for 483 observations. ## Section 2: Clinical Evidence Assessment Pull every relevant trial from ClinicalTrials.gov directly. Do not rely on press releases. Check trial status, primary endpoints, enrollment numbers, completion dates, and whether results have been posted. Cross-reference with PubMed for peer-reviewed publications. Note the journal impact factor and whether the study was industry-funded without independent replication. Red flags include: single-arm trials presented as if they were randomized controlled evidence, surrogate endpoints with no established correlation to clinical outcomes, patient populations that do not match the intended commercial market, and trials registered after data collection began. ## Section 3: Intellectual Property and Freedom to Operate Search USPTO (patents.google.com or the USPTO Patent Full-Text Database) for granted patents and pending applications. Confirm patent expiry dates, maintenance fee status, and whether any inter partes review (IPR) proceedings have been filed. Check the Orange Book for drug patents and exclusivity periods. Freedom-to-operate analysis requires legal counsel, but the report should flag any third-party patents in adjacent claims, any known litigation history on PACER, and how long the effective market exclusivity window realistically is after accounting for development timelines. ## Section 4: Financial Health and Capital Structure For public companies, pull every SEC filing directly from EDGAR: 10-K, 10-Q, 8-K, and proxy statements. Focus on cash runway relative to upcoming clinical or regulatory milestones, dilution history, debt covenants, and related-party transactions. For private companies, request audited financials and check whether the auditor issued a going-concern qualification. Revenue quality matters enormously in healthcare. Verify whether revenue is from product sales, milestone payments, or grants, and whether any large contracts have been renewed or are expiring. Confirm reimbursement status by checking CMS Coverage Database and relevant LCD/NCD policies. ## Section 5: Management and Team Verification Confirm credentials independently. Cross-reference claimed positions with LinkedIn, corporate press releases, and SEC proxy filings. Check the FDA's Debarment List and the OIG List of Excluded Individuals and Entities (both are free public databases). Review any litigation history on PACER involving executives personally. A strong management team in healthcare has a track record of navigating at least one full regulatory cycle, not just fundraising experience. ## Section 6: Competitive Landscape and Market Sizing Avoid market research reports that use top-down TAM calculations without clinical or payer validation. Instead, build the market estimate from the bottom up: confirmed patient population from epidemiology literature, realistic penetration rates benchmarked against comparable approved products, and actual reimbursement rates from CMS fee schedules or commercial payer policies. Map current and pipeline competitors by checking ClinicalTrials.gov for trials in the same indication with similar mechanisms, and the FDA's drug and device databases for already-approved alternatives. ## Section 7: Legal, Compliance, and ESG Liabilities Search PACER for litigation. Check the HHS Office of Inspector General advisory opinions and Corporate Integrity Agreement database for any prior enforcement actions against the company or its principals. Confirm that the company has a functional compliance program, especially if it bills Medicare or Medicaid. For devices and diagnostics manufactured outside the United States, verify that the manufacturing sites appear in FDA's establishment registration database and have no active import alerts. ## The Healthcare Due-Diligence Checklist - FDA approval status verified in primary FDA databases - No open warning letters, recalls, or 483 observations on manufacturing sites - ClinicalTrials.gov entries reviewed, not just press releases - Peer-reviewed publications confirmed on PubMed - Patent portfolio checked on USPTO with expiry and IPR status noted - SEC EDGAR filings reviewed directly (or audited financials for private companies) - Cash runway calculated against upcoming milestones - CMS reimbursement status confirmed - Management credentials and exclusions verified against OIG and FDA Debarment List - Competitive pipeline mapped on ClinicalTrials.gov - Litigation checked on PACER - OIG CIA database reviewed ## How MedFuel Intel Automates This Process Building a report that checks every one of these boxes manually takes dozens of hours and requires knowing exactly which databases to query in what sequence. MedFuel Intel's AI due-diligence engine pulls from FDA databases, SEC EDGAR, ClinicalTrials.gov, USPTO, PubMed, CMS, and OIG simultaneously, flags discrepancies between company claims and primary-source data, and delivers a structured report with source citations you can verify yourself. Run a free Red Flag Screener on any healthcare company at https://medfuelintel.com and see which sections of this checklist surface immediate concerns before you spend hours on deeper analysis. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/what-a-healthcare-investment-due-diligence-report-should-include). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.